{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT00807547",
      "orgStudyIdInfo": {
        "id": "SHX0562"
      },
      "organization": {
        "fullName": "ALK-Abelló A/S",
        "class": "INDUSTRY"
      },
      "briefTitle": "Intraseasonal Short-time Up-dosing With Alutard SQ Grasses",
      "officialTitle": "A Randomised, Parallel-group, Double-blind, Placebo-controlled, Multicentre Phase III Trial Assessing the Pharmacodynamic Efficacy and Safety of an Intra-seasonal Short-time Updosing Schedule for Alutard SQ"
    },
    "statusModule": {
      "statusVerifiedDate": "2015-12",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2008-04"
      },
      "primaryCompletionDateStruct": {
        "date": "2008-10",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2009-01",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2008-09-30",
      "studyFirstSubmitQcDate": "2008-12-11",
      "studyFirstPostDateStruct": {
        "date": "2008-12-12",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2015-12-28",
      "lastUpdatePostDateStruct": {
        "date": "2015-12-29",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "ALK-Abelló A/S",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false
    },
    "descriptionModule": {
      "briefSummary": "Test of pharmacodynamic efficacy and tolerability of a short-time intra-seasonal updosing"
    },
    "conditionsModule": {
      "conditions": [
        "Allergy"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "DOUBLE",
          "whoMasked": [
            "PARTICIPANT",
            "INVESTIGATOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 149,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Allergy vaccination",
          "type": "ACTIVE_COMPARATOR",
          "description": "Allergy vaccination by 6 subcutaneous injections to 10,000 SQ-U with 1-3 days intervals, continuation by 2 injections with 10,000 SQ-U with 2-4 weeks intervals",
          "interventionNames": [
            "Biological: Allergy vaccination (Alutard SQ)"
          ]
        },
        {
          "label": "Subcutaneous injections",
          "type": "PLACEBO_COMPARATOR",
          "description": "Placebo injections",
          "interventionNames": [
            "Biological: Allergy vaccination (Alutard SQ)"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "Allergy vaccination (Alutard SQ)",
          "description": "Alutard SQ grasses and rye, 8 subcutaneous injections, updosing to 10.000 SQ-U, duration of treatment 50 days",
          "armGroupLabels": [
            "Allergy vaccination",
            "Subcutaneous injections"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Changes from baseline in Immuno globuline E (IgE)-blocking factor",
          "timeFrame": "9 weeks"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Tolerability",
          "timeFrame": "9 weeks"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* history of grass pollen induced allergic rhinoconjunctivitis\n* positive skin prick test\n\nExclusion Criteria:\n\n* uncontrolled severe bronchial asthma\n* previous treatment with immunotherapy within the previous 5 years\n* contraindication for specific immunotherapy",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "65 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Ludger Klimek, MD",
          "affiliation": "Center for Rhinology and Allergology, An den Quellen 10, 65183 Wiesbaden, Germany",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Center for Rhinology and Allergology",
          "city": "Wiesbaden",
          "zip": "D-65183",
          "country": "Germany",
          "geoPoint": {
            "lat": 50.08601,
            "lon": 8.24435
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "23063373",
          "type": "RESULT",
          "citation": "Pfaar O, Wolf H, Klimek L, Schnitker J, Wustenberg E. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial. Clin Ther. 2012 Oct;34(10):2072-81. doi: 10.1016/j.clinthera.2012.09.006."
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        }
      ],
      "ancestors": [
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    }
  },
  "hasResults": false
}